Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors

Journal of Neuroimmunology

Volumn 262, Issue 1-2, 2013, Pages 11-18

  Song, Fei ^a,b   Bandara, Manoj ^a   Deol, Harvinder ^a   Loeb, Jeffrey A ^a   Benjamins, Joyce ^a,b   Lisak, Robert P ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

BDNF and TrkB tyrosine kinase receptor; Experimental autoimmune encephalomyelitis; Glatiramer acetate; Multiple sclerosis; Neuregulin1

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLATIRAMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NEU DIFFERENTIATION FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HETEROZYGOTE; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

BDNF AND TRKB TYROSINE KINASE RECEPTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLATIRAMER ACETATE; MULTIPLE SCLEROSIS; NEUREGULIN1;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HETEROZYGOTE DETECTION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUREGULIN-1; PEPTIDES; PROTEIN-TYROSINE KINASES; RECEPTOR, TRKB; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 84884147836     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.05.012     Document Type: Article

References (48)

1. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19045-19050.
2. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Bruck W., Arnon R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11358-11363.
3. Aharoni R., Saada R., Eilam R., Hayardeny L., Sela M., Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2012, 251:14-24.
4. Amor S., Puentes F., Baker D., van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010, 129:154-169.
5. Bredesen D.E., Rabizadeh S. p75NTR and apoptosis: Trk-dependent and Trk-independent effects. Trends Neurosci. 1997, 20:287-290.
6. Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res. Bull. 2010, 83:122-131.
7. Calvo M., Zhu N., Tsantoulas C., Ma Z., Grist J., Loeb J.A., Bennett D.L. Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J. Neurosci. 2010, 30:5437-5450.
8. Cannella B., Hoban C.J., Gao Y.L., Garcia-Arenas R., Lawson D., Marchionni M., Gwynne D., Raine C.S. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10100-10105.
9. Cannella B., Pitt D., Marchionni M., Raine C.S. Neuregulin and erbB receptor expression in normal and diseased human white matter. J. Neuroimmunol. 1999, 100:233-242.
10. Casaccia-Bonnefil P., Gu C., Chao M.V. Neurotrophins in cell survival/death decisions. Adv. Exp. Med. Biol. 1999, 468:275-282.
11. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 2003, 4:299-309.
12. Colombo E., Cordiglieri C., Melli G., Newcombe J., Krumbholz M., Parada L.F., Medico E., Hohlfeld R., Meinl E., Farina C. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J. Exp. Med. 2012, 209:521-535.
13. De Santi L., Annunziata P., Sessa E., Bramanti P. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Neurol. Sci. 2009, 287:17-26.
14. De Santi L., Polimeni G., Cuzzocrea S., Esposito E., Sessa E., Annunziata P., Bramanti P. Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment. Curr. Med. Chem. 2011, 18:1775-1784.
15. Derfuss T., Linington C., Hohlfeld R., Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J. Mol. Med. (Berl.) 2010, 88:753-761.
16. Esper R.M., Loeb J.A. Rapid axoglial signaling mediated by neuregulin and neurotrophic factors. J. Neurosci. 2004, 24:6218-6227.
17. Esper R.M., Pankonin M.S., Loeb J.A. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res. Rev. 2006, 51:161-175.
18. Falls D.L. Neuregulins and the neuromuscular system: 10years of answers and questions. J. Neurocytol. 2003, 32:619-647.
19. Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis?. J. Neurol. Sci. 2008, 265:93-96.
20. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
21. Kieseier B.C., Stuve O. A critical appraisal of treatment decisions in multiple sclerosis - old versus new. Nat. Rev. Neurol. 2011, 7:255-262.
22. Klein R., Smeyne R.J., Wurst W., Long L.K., Auerbach B.A., Joyner A.L., Barbacid M. Targeted disruption of the TrkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell 1993, 75:113-122.
23. Lalive P.H., Neuhaus O., Benkhoucha M., Burger D., Hohlfeld R., Zamvil S.S., Weber M.S. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011, 25:401-414.
24. Lee D.H., Geyer E., Flach A.C., Jung K., Gold R., Flugel A., Linker R.A., Luhder F. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. 2012, 123:247-258.
25. Linker R., Gold R., Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit. Rev. Immunol. 2009, 29:43-68.
26. Lisak R.P., Behan P.O. Experimental autoimmune demyelinating diseases: experimental allergic encephalomyelitis and experimental allergic neuritis. Biomedicine 1975, 22:81-87.
27. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
28. Loeb J.A. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 2007, 68:S38-S42. (discussion S43-54).
29. Loeb J.A., Fischbach G.D. Neurotrophic factors increase neuregulin expression in embryonic ventral spinal cord neurons. J. Neurosci. 1997, 17:1416-1424.
30. Loeb J.A., Khurana T.S., Robbins J.T., Yee A.G., Fischbach G.D. Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. Development 1999, 126:781-791.
31. Loeb J.A., Hmadcha A., Fischbach G.D., Land S.J., Zakarian V.L. Neuregulin expression at neuromuscular synapses is modulated by synaptic activity and neurotrophic factors. The Journal of neuroscience: the official journal of the Society for Neuroscience 2002, vol. 22:2206-2214. (ed.^eds.).
32. Luikart B.W., Nef S., Virmani T., Lush M.E., Liu Y., Kavalali E.T., Parada L.F. TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer collateral synapses. J. Neurosci. 2005, 25:3774-3786.
33. Ma Z., Li Q., An H., Pankonin M.S., Wang J., Loeb J.A. Targeting human epidermal growth factor receptor signaling with the neuregulin's heparin-binding domain. J. Biol. Chem. 2009, 284:32108-32115.
34. Ma Z., Wang J., Song F., Loeb J.A. Critical period of axoglial signaling between neuregulin-1 and brain-derived neurotrophic factor required for early Schwann cell survival and differentiation. J. Neurosci. 2011, 31:9630-9640.
35. Marchionni M.A., Cannella B., Hoban C., Gao Y.L., Garcia-Arenas R., Lawson D., Happel E., Noel F., Tofilon P., Gwynne D., Raine C.S. Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination. Adv. Exp. Med. Biol. 1999, 468:283-295.
36. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
37. Meyer D., Yamaai T., Garratt A., Riethmacher-Sonnenberg E., Kane D., Theill L.E., Birchmeier C. Isoform-specific expression and function of neuregulin. Development 1997, 124:3575-3586.
38. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2011, 10:209-219.
39. O'Neill E.J., Day M.J., Wraith D.C. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J. Neuroimmunol. 2006, 178:1-8.
40. Papenfuss T.L., Rogers C.J., Gienapp I., Yurrita M., McClain M., Damico N., Valo J., Song F., Whitacre C.C. Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains. J. Neuroimmunol. 2004, 150:59-69.
41. Penderis J., Woodruff R.H., Lakatos A., Li W.W., Dunning M.D., Zhao C., Marchionni M., Franklin R.J. Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur. J. Neurosci. 2003, 18:2253-2264.
42. Racke M.K., Lovett-Racke A.E. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J. Immunol. 2011, 186:1887-1890.
43. Ragheb S., Abramczyk S., Lisak D., Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Mult. Scler. 2001, 7:43-47.
44. Rakhade S.N., Yao B., Ahmed S., Asano E., Beaumont T.L., Shah A.K., Draghici S., Krauss R., Chugani H.T., Sood S., Loeb J.A. A common pattern of persistent gene activation in human neocortical epileptic foci. Ann. Neurol. 2005, 58:736-747.
45. Siffrin V., Vogt J., Radbruch H., Nitsch R., Zipp F. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010, 33:202-210.
46. Song F., Chiang P., Wang J., Ravits J., Loeb J.A. Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2012, 71:104-115.
47. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 2002, 125:75-85.
48. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.